Amgen Inc's new monoclonal antibody Prolia (denosumab) is the first "biologic therapy" approved by the FDA for the treatment of osteoporosis in menopausal women.
Anthony Luparello, PharmD Candidate
Advertisement
Articles by Anthony Luparello, PharmD Candidate
Advertisement
Latest Updated Articles
- A Closer Look at New FDA Actions: Amgen's Prolia
Published: August 17th 2010 | Updated:
Advertisement
Advertisement
Trending on Pharmacy Times
1
Expert Discusses Logistical Considerations and Future Research Needs for Radiopharmaceuticals
2
A Common Virus May Hold New Clues to Lupus
3
Zongertinib Shows Clinically Meaningful Efficacy in Advanced HER2-Mutant NSCLC
4
SHR-A1811 Plus Pertuzumab Improves Survival in HER2-Positive Metastatic Breast Cancer
5
